The footprint of gut microbiota in gallbladder cancer: a mechanistic review

Shujie Liu; Weijian Li; Weijian Li; Weijian Li; Weijian Li; Jun Chen; Jun Chen; Jun Chen; Jun Chen; Maolan Li; Maolan Li; Maolan Li; Maolan Li; Yajun Geng; Yajun Geng; Yajun Geng; Yajun Geng; Yingbin Liu; Yingbin Liu; Yingbin Liu; Yingbin Liu; Wenguang Wu; Wenguang Wu; Wenguang Wu; Wenguang Wu

doi:10.3389/fcimb.2024.1374238

Frontiers in Cellular and Infection Microbiology (May 2024)

The footprint of gut microbiota in gallbladder cancer: a mechanistic review

Shujie Liu,
Weijian Li,
Weijian Li,
Weijian Li,
Weijian Li,
Jun Chen,
Jun Chen,
Jun Chen,
Jun Chen,
Maolan Li,
Maolan Li,
Maolan Li,
Maolan Li,
Yajun Geng,
Yajun Geng,
Yajun Geng,
Yajun Geng,
Yingbin Liu,
Yingbin Liu,
Yingbin Liu,
Yingbin Liu,
Wenguang Wu,
Wenguang Wu,
Wenguang Wu,
Wenguang Wu

Affiliations

Shujie Liu: Joint Program of Nanchang University and Queen Mary University of London, Jiangxi Medical College of Nanchang University, Nanchang, Jiangxi, China
Weijian Li: Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Weijian Li: Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China
Weijian Li: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Weijian Li: Shanghai Research Center of Biliary Tract Disease, Shanghai, China
Jun Chen: Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Jun Chen: Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China
Jun Chen: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Jun Chen: Shanghai Research Center of Biliary Tract Disease, Shanghai, China
Maolan Li: Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Maolan Li: Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China
Maolan Li: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Maolan Li: Shanghai Research Center of Biliary Tract Disease, Shanghai, China
Yajun Geng: Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Yajun Geng: Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China
Yajun Geng: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Yajun Geng: Shanghai Research Center of Biliary Tract Disease, Shanghai, China
Yingbin Liu: Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Yingbin Liu: Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China
Yingbin Liu: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Yingbin Liu: Shanghai Research Center of Biliary Tract Disease, Shanghai, China
Wenguang Wu: Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Wenguang Wu: Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, China
Wenguang Wu: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Wenguang Wu: Shanghai Research Center of Biliary Tract Disease, Shanghai, China

DOI: https://doi.org/10.3389/fcimb.2024.1374238
Journal volume & issue: Vol. 14

Abstract

Read online

Gallbladder cancer (GBC) is the most common malignant tumor of the biliary system with the worst prognosis. Even after radical surgery, the majority of patients with GBC have difficulty achieving a clinical cure. The risk of tumor recurrence remains more than 65%, and the overall 5-year survival rate is less than 5%. The gut microbiota refers to a variety of microorganisms living in the human intestine, including bacteria, viruses and fungi, which profoundly affect the host state of general health, disease and even cancer. Over the past few decades, substantial evidence has supported that gut microbiota plays a critical role in promoting the progression of GBC. In this review, we summarize the functions, molecular mechanisms and recent advances of the intestinal microbiota in GBC. We focus on the driving role of bacteria in pivotal pathways, such as virulence factors, metabolites derived from intestinal bacteria, chronic inflammatory responses and ecological niche remodeling. Additionally, we emphasize the high level of correlation between viruses and fungi, especially EBV and Candida spp., with GBC. In general, this review not only provides a solid theoretical basis for the close relationship between gut microbiota and GBC but also highlights more potential research directions for further research in the future.

Published in Frontiers in Cellular and Infection Microbiology

ISSN: 2235-2988 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Science: Microbiology
Website: http://www.frontiersin.org/Cellular-and-Infection-Microbiology

About the journal

Abstract

Keywords